BRPI0918419A2 - nova formulação anticorpo - Google Patents
nova formulação anticorpoInfo
- Publication number
- BRPI0918419A2 BRPI0918419A2 BRPI0918419A BRPI0918419A BRPI0918419A2 BR PI0918419 A2 BRPI0918419 A2 BR PI0918419A2 BR PI0918419 A BRPI0918419 A BR PI0918419A BR PI0918419 A BRPI0918419 A BR PI0918419A BR PI0918419 A2 BRPI0918419 A2 BR PI0918419A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody formulation
- new antibody
- new
- formulation
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08164746 | 2008-09-19 | ||
PCT/EP2009/061692 WO2010031720A2 (en) | 2008-09-19 | 2009-09-09 | Novel antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0918419A2 true BRPI0918419A2 (pt) | 2015-11-24 |
Family
ID=41231968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0918419A BRPI0918419A2 (pt) | 2008-09-19 | 2009-09-09 | nova formulação anticorpo |
Country Status (16)
Country | Link |
---|---|
US (4) | US20100074903A1 (pt) |
EP (1) | EP2328559B1 (pt) |
JP (2) | JP5524967B2 (pt) |
KR (2) | KR20140019035A (pt) |
CN (1) | CN102159194A (pt) |
AU (1) | AU2009294680A1 (pt) |
BR (1) | BRPI0918419A2 (pt) |
CA (1) | CA2736198A1 (pt) |
CL (1) | CL2011000561A1 (pt) |
ES (1) | ES2531385T3 (pt) |
IL (1) | IL211190A0 (pt) |
MX (1) | MX2011002402A (pt) |
PE (1) | PE20110302A1 (pt) |
SG (1) | SG2014011365A (pt) |
WO (1) | WO2010031720A2 (pt) |
ZA (1) | ZA201101343B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
KR20120130757A (ko) * | 2010-02-26 | 2012-12-03 | 노보 노르디스크 에이/에스 | 안정한 항체 함유 조성물 |
CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
EP3733711A1 (en) * | 2010-10-06 | 2020-11-04 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
EP4088736A1 (en) | 2011-10-25 | 2022-11-16 | Prothena Biosciences Limited | Humanized anti-amyloid antibody formulations and methods |
AR090244A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Formulacion de anticuerpo anti-selectina p |
JP2016515515A (ja) * | 2013-03-15 | 2016-05-30 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | 抗プロラクチン受容体抗体製剤 |
CA2926089C (en) * | 2013-10-24 | 2022-08-30 | Medimmune, Llc | Stable, aqueous antibody formulations |
GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
EP3337828A1 (en) | 2015-08-18 | 2018-06-27 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018131893A1 (ko) | 2017-01-11 | 2018-07-19 | ㈜셀트리온 | 안정한 액체 제제 |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
EP4301411A1 (en) * | 2021-03-03 | 2024-01-10 | Allakos Inc. | Anti-siglec-8 antibody formulations |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800815A (en) * | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
US4783399A (en) | 1984-05-04 | 1988-11-08 | Scripps Clinic And Research Foundation | Diagnostic system for the detection of cytomegalovirus |
ATE169227T1 (de) | 1991-09-30 | 1998-08-15 | Biogen Inc | Hemmung von gefässverengung unter verwendung von anti-padgem antikörpern. |
JP3720352B2 (ja) * | 1992-05-05 | 2005-11-24 | アエレス バイオメディカル リミティド | P−セレクチンに対する抗体及びその利用 |
EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Igg抗体の安定な液体医薬製剤 |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
PT1737891E (pt) * | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
EP1871806A2 (en) * | 2005-03-08 | 2008-01-02 | Pharmacia & Upjohn Company LLC | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
EP2094729A1 (en) * | 2006-12-11 | 2009-09-02 | F.Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
-
2009
- 2009-09-09 ES ES09782818T patent/ES2531385T3/es active Active
- 2009-09-09 JP JP2011527294A patent/JP5524967B2/ja not_active Expired - Fee Related
- 2009-09-09 AU AU2009294680A patent/AU2009294680A1/en not_active Abandoned
- 2009-09-09 KR KR1020147001758A patent/KR20140019035A/ko active IP Right Grant
- 2009-09-09 SG SG2014011365A patent/SG2014011365A/en unknown
- 2009-09-09 WO PCT/EP2009/061692 patent/WO2010031720A2/en active Application Filing
- 2009-09-09 BR BRPI0918419A patent/BRPI0918419A2/pt not_active IP Right Cessation
- 2009-09-09 PE PE2011000614A patent/PE20110302A1/es not_active Application Discontinuation
- 2009-09-09 MX MX2011002402A patent/MX2011002402A/es active IP Right Grant
- 2009-09-09 KR KR1020117006209A patent/KR20110047232A/ko active Application Filing
- 2009-09-09 CN CN2009801368376A patent/CN102159194A/zh active Pending
- 2009-09-09 CA CA2736198A patent/CA2736198A1/en not_active Abandoned
- 2009-09-09 EP EP09782818.0A patent/EP2328559B1/en active Active
- 2009-09-15 US US12/559,555 patent/US20100074903A1/en not_active Abandoned
-
2011
- 2011-02-10 IL IL211190A patent/IL211190A0/en not_active IP Right Cessation
- 2011-02-18 ZA ZA2011/01343A patent/ZA201101343B/en unknown
- 2011-03-17 CL CL2011000561A patent/CL2011000561A1/es unknown
-
2012
- 2012-07-30 US US13/561,233 patent/US20120321638A1/en not_active Abandoned
-
2013
- 2013-04-01 US US13/854,254 patent/US20130209478A1/en not_active Abandoned
- 2013-09-19 US US14/031,199 patent/US20140093512A1/en not_active Abandoned
-
2014
- 2014-01-17 JP JP2014006650A patent/JP2014094958A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2531385T3 (es) | 2015-03-13 |
IL211190A0 (en) | 2011-04-28 |
CA2736198A1 (en) | 2010-03-25 |
JP2012502942A (ja) | 2012-02-02 |
CN102159194A (zh) | 2011-08-17 |
PE20110302A1 (es) | 2011-05-21 |
WO2010031720A3 (en) | 2010-09-23 |
JP5524967B2 (ja) | 2014-06-18 |
AU2009294680A1 (en) | 2010-03-25 |
MX2011002402A (es) | 2011-04-05 |
WO2010031720A2 (en) | 2010-03-25 |
US20120321638A1 (en) | 2012-12-20 |
KR20140019035A (ko) | 2014-02-13 |
ZA201101343B (en) | 2011-11-30 |
EP2328559B1 (en) | 2015-01-07 |
SG2014011365A (en) | 2014-05-29 |
US20140093512A1 (en) | 2014-04-03 |
US20100074903A1 (en) | 2010-03-25 |
US20130209478A1 (en) | 2013-08-15 |
CL2011000561A1 (es) | 2011-09-02 |
EP2328559A2 (en) | 2011-06-08 |
JP2014094958A (ja) | 2014-05-22 |
KR20110047232A (ko) | 2011-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2018009I2 (no) | Dupilumab | |
NO2018006I1 (no) | Atezolizumab | |
BRPI0918419A2 (pt) | nova formulação anticorpo | |
NL300879I2 (nl) | Alirocumab | |
DK3072906T3 (da) | Antistofformulering | |
BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
DK2234600T3 (da) | Antistofformulering | |
BRPI1006519A2 (pt) | formulação de anticorpos | |
BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
BRPI0908269A2 (pt) | aplicador | |
BRPI0906749A2 (pt) | Composição | |
BRPI0913808A2 (pt) | composição | |
DK2370462T3 (da) | Glucagon-analoger | |
DK2252395T3 (da) | Afsvovlingsmaterialer | |
BRPI0917231A2 (pt) | composição | |
BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
BRPI0914098A2 (pt) | biosensor | |
DE112009001946A5 (de) | Mobelauszugsführung | |
BRPI0912769A2 (pt) | anticorpos anti-pirb | |
DK2382224T3 (da) | Metalhydracid-materialer | |
DK2254963T3 (da) | Kerne-skal-flowforbedrer | |
NO20083166L (no) | Fortoyningsarrangement | |
NO20082318L (no) | Bolgeenergigenereringssystem | |
BRPI0917584A2 (pt) | composição | |
ATE554652T1 (de) | Molluskizid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |